- Home
- ESLA vs RDI Comparison
ESLA vs RDI Comparison
Compare ESLA & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- RDI
- Stock Information
- Founded
- ESLA 2021
- RDI 1937
- Country
- ESLA United States
- RDI United States
- Employees
- ESLA N/A
- RDI N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- RDI Movies/Entertainment
- Sector
- ESLA Health Care
- RDI Consumer Discretionary
- Exchange
- ESLA Nasdaq
- RDI Nasdaq
- Market Cap
- ESLA 35.9M
- RDI 35.7M
- IPO Year
- ESLA N/A
- RDI N/A
- Fundamental
- Price
- ESLA $1.12
- RDI $1.54
- Analyst Decision
- ESLA Strong Buy
- RDI
- Analyst Count
- ESLA 1
- RDI 0
- Target Price
- ESLA $16.00
- RDI N/A
- AVG Volume (30 Days)
- ESLA 35.9K
- RDI 55.8K
- Earning Date
- ESLA 08-12-2025
- RDI 11-13-2025
- Dividend Yield
- ESLA N/A
- RDI N/A
- EPS Growth
- ESLA N/A
- RDI N/A
- EPS
- ESLA N/A
- RDI N/A
- Revenue
- ESLA N/A
- RDI $219,213,000.00
- Revenue This Year
- ESLA N/A
- RDI $5.21
- Revenue Next Year
- ESLA N/A
- RDI $11.45
- P/E Ratio
- ESLA N/A
- RDI N/A
- Revenue Growth
- ESLA N/A
- RDI 7.59
- 52 Week Low
- ESLA $0.63
- RDI $1.17
- 52 Week High
- ESLA $1.78
- RDI $1.88
- Technical
- Relative Strength Index (RSI)
- ESLA 63.62
- RDI 57.90
- Support Level
- ESLA $1.04
- RDI $1.47
- Resistance Level
- ESLA $1.23
- RDI $1.60
- Average True Range (ATR)
- ESLA 0.07
- RDI 0.07
- MACD
- ESLA 0.01
- RDI -0.01
- Stochastic Oscillator
- ESLA 56.00
- RDI 50.00
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.